[go: up one dir, main page]

SI4058148T1 - Dozirni režim za sredstva proti BCMA - Google Patents

Dozirni režim za sredstva proti BCMA

Info

Publication number
SI4058148T1
SI4058148T1 SI202030419T SI202030419T SI4058148T1 SI 4058148 T1 SI4058148 T1 SI 4058148T1 SI 202030419 T SI202030419 T SI 202030419T SI 202030419 T SI202030419 T SI 202030419T SI 4058148 T1 SI4058148 T1 SI 4058148T1
Authority
SI
Slovenia
Prior art keywords
bcma
agents
dosing regimen
regimen
dosing
Prior art date
Application number
SI202030419T
Other languages
English (en)
Inventor
Julia Stieglmaier
Birgit Huber
Alexander Minella
Vijay Upreti
Original Assignee
Amgen Research (Munich) Gmbh
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68581157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI4058148(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Research (Munich) Gmbh, Amgen Inc. filed Critical Amgen Research (Munich) Gmbh
Publication of SI4058148T1 publication Critical patent/SI4058148T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SI202030419T 2019-11-11 2020-05-08 Dozirni režim za sredstva proti BCMA SI4058148T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19208417.6A EP3819007B1 (en) 2019-11-11 2019-11-11 Dosing regimen for anti-bcma agents
PCT/EP2020/062876 WO2021094000A1 (en) 2019-11-11 2020-05-08 Dosing regimen for anti-bcma agents
EP20729951.2A EP4058148B1 (en) 2019-11-11 2020-05-08 Dosing regimen for anti-bcma agents

Publications (1)

Publication Number Publication Date
SI4058148T1 true SI4058148T1 (sl) 2024-06-28

Family

ID=68581157

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201930825T SI3819007T1 (sl) 2019-11-11 2019-11-11 Režim odmerjanja sredstev proti BCMA
SI202030419T SI4058148T1 (sl) 2019-11-11 2020-05-08 Dozirni režim za sredstva proti BCMA

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201930825T SI3819007T1 (sl) 2019-11-11 2019-11-11 Režim odmerjanja sredstev proti BCMA

Country Status (20)

Country Link
US (1) US20210139584A1 (sl)
EP (3) EP3819007B1 (sl)
JP (2) JP2022554362A (sl)
AU (1) AU2020381671A1 (sl)
CA (1) CA3155069A1 (sl)
DK (2) DK3819007T3 (sl)
ES (2) ES2987783T3 (sl)
FI (2) FI3819007T3 (sl)
HR (2) HRP20241281T1 (sl)
HU (2) HUE068401T2 (sl)
LT (2) LT3819007T (sl)
MA (1) MA47888B1 (sl)
MX (1) MX2022005628A (sl)
PL (2) PL3819007T3 (sl)
PT (2) PT3819007T (sl)
RS (2) RS65943B1 (sl)
SI (2) SI3819007T1 (sl)
SM (2) SMT202400373T1 (sl)
TW (1) TW202118784A (sl)
WO (1) WO2021094000A1 (sl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio Inc anticorpos apenas de cadeia pesada anti-bcma
WO2022103781A1 (en) * 2020-11-10 2022-05-19 Amgen Inc. Methods for administering a bcma x cd3 binding molecule
WO2023098846A1 (zh) * 2021-12-03 2023-06-08 江苏先声药业有限公司 抗bcma纳米抗体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
HRP20000714B1 (en) 1998-04-21 2006-03-31 Micromet Ag NOVEL CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
DE69911793T2 (de) 1998-07-28 2004-08-12 Micromet Ag Heterominikörper
JP4948174B2 (ja) 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
ES2432792T5 (es) 2007-04-03 2023-01-16 Amgen Res Munich Gmbh Dominio de unión a CD3-épsilon específico de especies cruzadas
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US10981998B2 (en) 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
US8748380B2 (en) 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
WO2012059486A1 (en) 2010-11-01 2012-05-10 Novozymes Biopharma Dk A/S Albumin variants
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
KR20140027307A (ko) 2011-05-05 2014-03-06 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
US20130078250A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
WO2013026833A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
BR112015010318A2 (pt) 2012-11-08 2017-08-22 Albumedix As Variantes de albumina
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
US20160257748A1 (en) 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
SI3988117T1 (sl) 2015-04-13 2025-03-31 Pfizer Inc. Terapevtska protitelesa in njihova uporaba
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
LT3331910T (lt) 2015-08-03 2020-03-25 Engmab Sarl Monokloniniai antikūnai prieš žmogaus b ląstelių brendimo antigeną (bcma)
JO3799B1 (ar) 2015-08-17 2021-01-31 Janssen Pharmaceutica Nv الأجسام المضادة ل bcma، جزيئات ربط الانتيجين ثنائية التحديد التي تربط bcma و cd3، و استخداماتها
KR20240118898A (ko) * 2016-02-03 2024-08-05 암젠 리서치 (뮌헨) 게엠베하 Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
KR102687833B1 (ko) 2016-11-02 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도
EP3694529B1 (en) 2017-10-13 2024-06-26 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
EP3796912B1 (en) 2018-05-23 2023-02-15 Celgene Corporation Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
TW202028239A (zh) * 2018-09-28 2020-08-01 美商安進公司 針對可溶性bcma之抗體
EP3911371A4 (en) * 2019-01-18 2023-04-26 University of Southern California METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY
EP3986569A1 (en) 2019-06-24 2022-04-27 Novartis AG Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
ES2948136T3 (es) 2019-07-18 2023-08-31 Barberan Latorre Jesus Francisco Cabezal, máquina y procedimiento de impresión digital en sustratos
WO2021092056A1 (en) 2019-11-05 2021-05-14 Engmab Sàrl Methods of treatment with antibodies against bcma and cd3
CA3194771A1 (en) * 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
WO2022103781A1 (en) * 2020-11-10 2022-05-19 Amgen Inc. Methods for administering a bcma x cd3 binding molecule

Also Published As

Publication number Publication date
JP2025170264A (ja) 2025-11-18
DK4058148T5 (da) 2024-07-22
EP4424709A2 (en) 2024-09-04
HRP20240553T1 (hr) 2024-07-05
PT3819007T (pt) 2024-09-20
FI4058148T3 (fi) 2024-05-06
ES2987070T3 (es) 2024-11-13
FI3819007T3 (fi) 2024-09-25
EP4424709A3 (en) 2024-12-11
EP4058148A1 (en) 2022-09-21
EP4058148B1 (en) 2024-03-13
MA47888B1 (fr) 2024-10-31
EP3819007A1 (en) 2021-05-12
HUE068401T2 (hu) 2024-12-28
PL3819007T3 (pl) 2024-11-18
AU2020381671A1 (en) 2022-03-31
DK3819007T3 (da) 2024-09-30
WO2021094000A1 (en) 2021-05-20
PT4058148T (pt) 2024-05-03
RS65943B1 (sr) 2024-10-31
SMT202400165T1 (it) 2024-05-14
TW202118784A (zh) 2021-05-16
JP2022554362A (ja) 2022-12-28
DK4058148T3 (da) 2024-05-06
MX2022005628A (es) 2022-06-14
US20210139584A1 (en) 2021-05-13
RS65581B1 (sr) 2024-06-28
HUE066166T2 (hu) 2024-07-28
SI3819007T1 (sl) 2024-10-30
LT3819007T (lt) 2024-10-10
PL4058148T3 (pl) 2024-09-16
SMT202400373T1 (it) 2024-11-15
CA3155069A1 (en) 2021-05-20
HRP20241281T1 (hr) 2024-12-06
EP3819007B1 (en) 2024-07-10
ES2987783T3 (es) 2024-11-18
LT4058148T (lt) 2024-05-27

Similar Documents

Publication Publication Date Title
PT3347054T (pt) Regimes de dosagem para conjugados fármaco-anticorpo anti-tf
GB201713653D0 (en) Dosage regimen
CA194973S (en) Package
PT4340842T (pt) Sotorasib para utilização no tratamento de cancro
LT4058148T (lt) Agentų prieš bcma dozavimo režimas
PL3733041T3 (pl) Urządzenie dozujące
GB2588686B (en) Chemical-agent dosing apparatus
IL291432A (en) Dosage for anti-tryptase antibodies
IL280515A (en) Dosing regimens for algolix
IL308095A (en) Dosing regimens
HK40074182A (en) Dosing regimen for anti-dll3 agents
IL274375A (en) Dosing regimen of edsalonacant for the treatment of muscular dystrophy
GB201902454D0 (en) Dosage regimen
GB201910963D0 (en) Dosing unit
HK40054775A (en) Dosing regimens for elagolix
GB201903654D0 (en) Dosing device
GB201919139D0 (en) Easier-opening packages
GB201720519D0 (en) Dosing regimen
CA191469S (en) Package
GB201718106D0 (en) Dosing regimen
GB201718000D0 (en) Dosing regimen
GB201717694D0 (en) Dosing regimen
GB201906594D0 (en) Dosing system
CA207713S (en) Package
CA207714S (en) Package